Skip to main content

Critical Care Reviews Newsletter

Newsletter 553  |  July 25th 2022

Please support our work to share science

The LOVIT Trial Visual Abstract

Welcome to the 553rd Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the week July 11th to 17th. After the demands of CCR22, we're just one week behind and should catch up fully this week!

The highlights of this week's edition are randomised controlled trials on erythropoietin for hypoxic–ischemic encephalopathy in newborns & nicotine patches in mechanically ventilated patients with severe COVID‑19; systematic reviews and meta analyses on spirituality in serious illness & beta-blocker treatment in the critically ill; and observational studies on presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures & bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation.

There are also guidelines on glycemic management of critically ill patients & indications and triaging for adult transthoracic echocardiography; narrative reviews on intracranial pressure & imaging the acute respiratory distress syndrome; and commentaries on virtual reality in intensive care & point-of-care ultrasound for the diagnosis and management of acute heart failure.

If you only have time to read one review article this week, try this one on poor physical recovery after critical illness.

We've started an Instagram account, where we'll post various media, including photographs from CCR22, and our latest addition to the platform, visual abstracts on the major critical care trials. We're delighted to say Dr Jakub Fronczek, from Cracow, Poland, has joined the CCR team and will lead on the development of these.

If you'd like to support our work, please join our CCR Supporter Club, where you can contribute as little as the price of a cup of coffee per month or make a one-off donation.

I hope you find this newsletter useful.

Until next week



Supported by

My Intensive Care Logo